Galectin Therapeutics

Historical price data

Galectin Therapeutics' mission is to develop novel therapeutics for chronic liver disease and cancer by inhibiting the galectin-3 protein. Its primary achievement is advancing belapectin into a pivotal Phase 2b/3 trial (NAVIGATE) for MASH cirrhosis with portal hypertension, positioning it as a potential first-to-market therapy for this life-threatening condition. The company's strategy is to clinically validate its galectin-3 platform in high-need fibrotic and oncologic indications, creating significant value through targeted clinical development and potential strategic partnerships.

Platform based on complex carbohydrate compounds designed to selectively inhibit galectin-3, a protein central to fibrosis, inflammation, and cancer immune evasion.

Competition in early-stage MASH is intense, but the MASH cirrhosis segment is relatively open. Belapectin's primary competition is the current standard of care (transplant), though other drug classes are advancing into later-stage trials.